Information on EC 2.3.1.67 - 1-alkylglycerophosphocholine O-acetyltransferase

Word Map on EC 2.3.1.67
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
2.3.1.67
-
RECOMMENDED NAME
GeneOntology No.
1-alkylglycerophosphocholine O-acetyltransferase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine = CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
show the reaction diagram
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Acyl group transfer
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Ether lipid metabolism
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
acetyl-CoA:1-alkyl-sn-glycero-3-phosphocholine 2-O-acetyltransferase
-
CAS REGISTRY NUMBER
COMMENTARY hide
76773-96-1
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
evolution
metabolism
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA
1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA
show the reaction diagram
acetyl-CoA + 1-acyl-sn-glycero-3-phosphate
CoA + 2-acetyl-1-acyl-sn-glycero-3-phosphate
show the reaction diagram
-
-
-
?
acetyl-CoA + 1-acyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-acyl-sn-glycero-3-phosphocholine
show the reaction diagram
-
-
-
?
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
show the reaction diagram
acetyl-CoA + 1-hexadecyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-hexadecyl-sn-glycero-3-phosphocholine
show the reaction diagram
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphocholine
?
show the reaction diagram
-
-
-
-
?
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-6-phosphocholine
show the reaction diagram
-
final step in remodelling pathway of PAF biosynthesis
-
?
acetyl-CoA + 1-octadecyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
show the reaction diagram
acetyl-CoA + 1-palmitoyl-2-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-palmitoyl-sn-glycero-3-phosphocholine
show the reaction diagram
acetyl-CoA + acetyl-phosphatidylcholine
?
show the reaction diagram
-
-
-
-
?
acetyl-CoA + acyl-lyso-glycero-3-phosphocholine
CoA + acetyl-acyl-glycero-3-phosphocholine
show the reaction diagram
acetyl-CoA + alk-1-enyl-lyso-glycero-3-phosphoethanolamine
CoA + acetyl-alk-1-enyl-glycero-3-phosphoethanolamine
show the reaction diagram
acetyl-CoA + alkyl-lyso-glycero-3-phosphoethanolamine
CoA + 2-acetyl-alkyl-glycero-3-phosphoethanolamine
show the reaction diagram
acetyl-CoA + alkyl-lyso-monomethylethanamine
?
show the reaction diagram
acetyl-CoA + alkyl-lyso-N',N'-dimethylethanamine
?
show the reaction diagram
acetyl-CoA + alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
show the reaction diagram
acetyl-CoA + hexadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-hexadecyl-sn-glycero-3-phosphocholine
show the reaction diagram
acetyl-CoA + lyso-phosphatidylcholine
CoA + 2-acetyl-1-acylphosphatidylcholine
show the reaction diagram
-
-
-
?
acetyl-CoA + lyso-phosphatidylethanolamine
CoA + 2-acetyl-1-acyl-phosphatidylethanolamine
show the reaction diagram
-
-
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
show the reaction diagram
acetyl-CoA + octadecyl-lyso-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-octadecyl-sn-glycero-3-phosphocholine
show the reaction diagram
acetyl-CoA + phosphatidylcholine
?
show the reaction diagram
-
-
-
-
?
lyso-platelt activating factor + acetyl-CoA
?
show the reaction diagram
-
-
-
-
?
oleoyl-CoA + alkyl-lyso-glycero-3-phosphoethanolamine
CoA + 1-alkyl-2-oleoyl-glycero-3-phosphoethanolamine
show the reaction diagram
-
10% of the activity observed in presence of acetyl-CoA
-
?
palmitoyl-CoA + alkyl-lyso-glycero-3-phosphoethanolamine
CoA + acetyl-2-palmitoyl-glycero-3-phosphoethanolamine
show the reaction diagram
-
5% of the activity observed in presence of acetyl-CoA
-
?
propionyl-CoA + alkyl-lyso-glycero-phosphocholine
CoA + 2-propionyl-1-alkyl-sn-glycero-3-phosphocholine
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
1-O-hexadecyl-sn-glycero-3-phosphocholine + acetyl-CoA
1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine + CoA
show the reaction diagram
acetyl-CoA + 1-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine
show the reaction diagram
acetyl-CoA + 1-O-alkyl-sn-glycero-3-phosphocholine
CoA + 2-acetyl-1-alkyl-6-phosphocholine
show the reaction diagram
-
final step in remodelling pathway of PAF biosynthesis
-
?
acetyl-CoA + lyso-platelet-activating factor
platelet-activating factor + CoA
show the reaction diagram
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
acetyl-CoA
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
selenium
-
as a consequence of Se deficiency increased phospholipase D activity and phosphatidic acid production contribute to enhanced enzyme activity, which results in an overall increase in platelet activating factor. The regulation of enzyme activity by Se may constitute an important control mechanism for the maintenance of levels of platelet activating factor in endothelial cells
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-epicatechin-3-O-gallate
-
IC50: 0.072 mM
(-)-epigallocatechin
-
IC50: 0.073 mM
(-)-epigallocatechin-3-O-gallate
-
IC50: 0.046 mM
(4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diyl)bis[(2R,3R)-5,7-dihydroxy-3,4-dihydro-2H-chromene-2,3-diyl] bis(3,4,5-trihydroxybenzoate)
-
-
1,2,3,4,6-pentagalloyl-beta-D-glucose
-
IC50: 0.026 mM
1,4-diacetoxy-2-methoxy-5-methyl-3-tetradecanoyloxybenzene
-
1-acyl-sn-glycero-3-phosphate
-
competitive inhibition for 1-alkyl-sn-glycero-3-phosphate
1-methoxyphaseolidin
-
IC50: 0.048 mM
1-methoxyphaseolin
-
IC50: 0.057 mM
1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine
-
irreversible inhibition dependent of both 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine and enzyme concentration
1-O-alkyl-sn-glycero-3-phosphocholine
-
inhibition at high concentrations due to its detergent effect
2-mercaptoethanol
-
-
2-methoxy-1,3,4-trihydroxy-5-methylbenzene
i.e. 2-methoxy-1,3,4-trihydroxy-5-methylbenzene, isolated from Penicillium sp. strain F33
-
2-methoxy-5-methyl-1,3,4-triacetoxybenzene
-
2-methoxy-5-methyl-3-octadecanoyloxy-1,4-benzoquinone
-
2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone
3,4-dichloro-1-(4,5-dichloro-2-methoxyphenyl)-1H-pyrrole-2,5-dione
3,4-dihydroxy-1,2-dimethoxy-5-methylbenzene
-
3-acetoxy-2-methoxy-5-methyl-1,4-benzoquinone
-
3-chloro-1-(3-chloro-4-methoxyphenyl)-4-(2-methoxyphenoxy)-1H-pyrrole-2,5-dione
3-chloro-1-(4,5-dichloro-2-methoxyphenyl)-4-(2-hydroxyanilino)-1H-pyrrole-2,5-dione
3-chloro-4-(morpholin-4-yl)-1-(4-phenoxyphenyl)-1H-pyrrole-2,5-dione
3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
3-hexanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
-
3-hydroxy-2-methoxy-5-methyl-1,4-benzoquinone
-
4-(1-Naphthylvinyl)pyridine
-
IC50: 0.043 mM
6,8-diprenylgenistein
-
IC50: 0.019 mM
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid
-
i.e. Trolox, reduces production of platelet-activating factor (PAF) in H2O2-treated HUVEC cells
acetyl-salicylic acid
Arachidonoyl-CoA
-
-
ascorbic acid
-
18.3% inhibition at 1 mM
baicalein
butyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
CaCl2
chiyusaponin
-
IC50: 0.2 mM
Decanoic acid
-
dexamethasone
-
2 mg/kg for 3 days in liver and spleen
dihydrofumigatin
i.e. 2-methoxy-1,3,4-trihydroxy-5-methylbenzene, isolated from Penicillium sp. strain F33
diisopropylfluorophosphate
dithiothreitol
-
-
dodecanoic acid
-
ebselen
-
suppresses alkyl-2-acetyl-sn-glycero-3-phosphocholine synthesis by 7.7% and 26.6% in presence of glutathione
farnesyl gallate
-
IC50: 0.066 mM
gallic acid
-
5.3% inhibition at 0.1 mM
geranyl gallate
-
IC50: 0.089 mM
glutathione
-
suppresses alkyl-2-acetyl-sn-glycero-3-phosphocholine synthesis by 18.9%
H2O2
-
8% inhibition at 1 mM
honokiol
indomethacin
licoricidin
-
IC50: 0.0077 mM
lopinavir-r
-
; remaining activity in human mesangial cells: 76%. By contrast no effect on activity is observed in blood of naiive patients treated with the drug
luteolin
-
IC50: 0.045 mM
lysophosphatidylcholine
-
inhibition at high concentrations due to its detergent effect
magnolol
medroxyprogesterone
-
50 mg/kg in liver
methyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
methyl 4-[3-chloro-2,5-dioxo-4-(4-sulfamoylanilino)-2,5-dihydro-1H-pyrrol-1-yl]benzoate
MgATP2-
-
32% and 54% inhibition at 0.125 and 1 mM respectively in neuronal nuclear fraction
MgCl2
MnCl2
myricetin
-
suppresses alkyl-2-acetyl-sn-glycero-3-phosphocholine synthesis by 17%
myristic acid
-
N-acetylcysteine
-
reduces production of platelet-activating factor (PAF) in H2O2-treated HUVEC cells
n-dodecyl gallate
-
IC50: 0.091 mM
N-ethylmaleimide
-
-
nordihydroguaiaretic acid
Octanoic acid
-
oleic acid
-
1-acyl lysolipids less inhibited than the 1-alkyl species
oleoyl-CoA
p-bromophenacyl bromide
p-chloromercuribenzoate
-
-
palmitic acid
-
palmitoyl-CoA
palmitoyllyso-glycero-3-phosphocholine
-
phenylmethylsulfonyl fluoride
-
30% inhibition at 50 mM
phosphatidic acid
-
-
procyanidin B-2,3,3'-di-O-gallate
-
IC50: 0.031 mM
procyanidin B-5,3,3'-di-O-gallate
-
IC50: 0.024 mM
propan-2-yl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
propan-2-yl 4-(3-chloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
propan-2-yl 4-[3-chloro-4-(2-hydroxyanilino)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
propan-2-yl 4-[3-chloro-4-(morpholin-4-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
propanolol
-
-
propyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
pyrrolidinecarbodithioic acid
-
i.e. PDTC, reduces production of platelet-activating factor (PAF) in H2O2-treated HUVEC cells
quercetin
resveratrol
-
0.157 microM, results in 50% inhibition in interleukin 1beta effect on catalytic activity
serine/threonine phosphatase
-
diminishes rates of acetylation for 1-alkyl-sn-glycero-3-phosphocholine and 1-acyl-sn-glycero-3-phosphocholine
-
sodium dodecylsulfate
-
inactivation at 0.1%
tenofovir-DF
-
; remaining activity in human mesangial cells: 32%. By contrast no effect on activity is observed in blood of naiive patients treated with the drug
tetradecanoic acid
-
-
theaflavin
-
IC50: 0.032 mM
theaflavin-3'-O-gallate
-
IC50: 0.039 mM
theaflavin-3,3'-di-O-gallate
-
IC50: 0.028 mM
theaflavin-3-O-gallate
-
IC50: 0.058 mM
theasinensin A
-
IC50: 0.029 mM
Trifluoperazine
-
-
Triton X-100
-
75 and 95% inhibition at 0.2 and 0.6 mM respectively due to detergent
tyrosol
-
0.048 microM, results in 50% inhibition in interleukin 1beta effect on catalytic activity
Urea
-
inactivation at 8 mM
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
A23187
-
-
AMP-dependent protein kinase
-
bovine serum albumin
-
optimal concentration of 1-1.5 mg/ml at short incubation periods and 2-2.5 mg bovine serum albumin/ml during longer incubation periods
-
calcium calmodulin-dependent protein kinase
-
-
-
diethyl maleate
-
enhanced 3-fold upon treatment with 5 mM H2O2
H2O2
-
increased in concentration-dependent manner, fast but transitory activation, concentrations of H2O2 ranging from 1 to 10 mM, maximal effect at 10 mM, maximum reached within 20 min
interleukin 1beta
-
2.5 ng/ml, induces 2fold increase in intracellular platelet activating factor levels against non-stimulated cells, as well as in the specific activity of acetyl-CoA:lyso-PAF acetyltransferase at 3 h. Effect is inhibited in presence of tyrosol or resveratrol
-
lipopolysaccharide
-
activity increases in a time-dependent fashion, maximal activation at 0.010 mg/ml lipopolysaccharide
mitogen-activated protein p38
-
MAP kinase p38
-
N-formyl-methionyl-leucyl-phenylalanine
-
stimulation is dependent on the preincubation of cells with cytochalasin B, addition of tumor necrosis factor increases 50% alkyl-2-acetyl-sn-glycero-3-phosphocholine production
NaF
-
slightly increases activity
additional information
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.011
1-acyl-sn-glycero-3-phosphate
-
-
0.009
1-alkyl-sn-glycero-3-phosphate
-
-
0.018
1-alkyl-sn-glycero-3-phosphocholine
-
-
0.1282
1-O-hexadecyl-sn-glycero-3-phosphocholine
apparent KM
0.067 - 0.274
acetyl-CoA
0.046
butyryl-CoA
-
-
0.02
Hexanoyl-CoA
-
-
0.00921
lyso-platelet-activating factor
-
total membrane fractions of mesangial cells
0.128
propionyl-CoA
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.072
(-)-epicatechin-3-O-gallate
Oryctolagus cuniculus
-
IC50: 0.072 mM
0.073
(-)-epigallocatechin
Oryctolagus cuniculus
-
IC50: 0.073 mM
0.046
(-)-epigallocatechin-3-O-gallate
Oryctolagus cuniculus
-
IC50: 0.046 mM
0.029
(4,4',5,5',6,6'-hexahydroxybiphenyl-2,2'-diyl)bis[(2R,3R)-5,7-dihydroxy-3,4-dihydro-2H-chromene-2,3-diyl] bis(3,4,5-trihydroxybenzoate)
Oryctolagus cuniculus
-
IC50: 0.029 mM
0.026
1,2,3,4,6-pentagalloyl-beta-D-glucose
Oryctolagus cuniculus
-
IC50: 0.026 mM
0.5
1,4-diacetoxy-2-methoxy-5-methyl-3-tetradecanoyloxybenzene
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.048
1-methoxyphaseolidin
Rattus norvegicus
-
IC50: 0.048 mM
0.057
1-methoxyphaseolin
Rattus norvegicus
-
IC50: 0.057 mM
0.101
2-methoxy-1,3,4-trihydroxy-5-methylbenzene
Mus musculus
Q8BYI6
pH 6.9, 37°C
-
0.5
2-methoxy-5-methyl-1,3,4-triacetoxybenzene
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.391
2-methoxy-5-methyl-3-octadecanoyloxy-1,4-benzoquinone
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.02
2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone
0.0171
3,4-dichloro-1-(4,5-dichloro-2-methoxyphenyl)-1H-pyrrole-2,5-dione
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.166
3,4-dihydroxy-1,2-dimethoxy-5-methylbenzene
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.121
3-acetoxy-2-methoxy-5-methyl-1,4-benzoquinone
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.00758
3-chloro-1-(3-chloro-4-methoxyphenyl)-4-(2-methoxyphenoxy)-1H-pyrrole-2,5-dione
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.02
3-chloro-1-(4,5-dichloro-2-methoxyphenyl)-4-(2-hydroxyanilino)-1H-pyrrole-2,5-dione
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.00116
3-chloro-4-(morpholin-4-yl)-1-(4-phenoxyphenyl)-1H-pyrrole-2,5-dione
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.003
3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
0.139
3-hexanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.109
3-hydroxy-2-methoxy-5-methyl-1,4-benzoquinone
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.043
4-(1-Naphthylvinyl)pyridine
Rattus norvegicus
-
IC50: 0.043 mM
0.019
6,8-diprenylgenistein
Rattus norvegicus
-
IC50: 0.019 mM
1.52
acetyl-salicylic acid
Bos taurus
-
IC50: 1.52 mM
0.105 - 0.148
baicalein
0.00033
butyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.2
chiyusaponin
Rattus norvegicus
-
IC50: 0.2 mM
0.5
Decanoic acid
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.419
dodecanoic acid
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.066
farnesyl gallate
Oryctolagus cuniculus
-
IC50: 0.066 mM
0.089
geranyl gallate
Oryctolagus cuniculus
-
IC50: 0.089 mM
0.06 - 0.15
honokiol
0.26
indomethacin
Bos taurus
-
IC50: 0.26 mM
0.0077
licoricidin
Rattus norvegicus
-
IC50: 0.0077 mM
0.045
luteolin
Rattus norvegicus
-
IC50: 0.045 mM
0.07 - 0.15
magnolol
0.0116
methyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.02
methyl 4-[3-chloro-2,5-dioxo-4-(4-sulfamoylanilino)-2,5-dihydro-1H-pyrrol-1-yl]benzoate
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.183
myristic acid
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.091
n-dodecyl gallate
Oryctolagus cuniculus
-
IC50: 0.091 mM
0.06 - 0.29
nordihydroguaiaretic acid
0.5
Octanoic acid
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.5
palmitic acid
Mus musculus
Q8BYI6
pH 6.9, 37°C
0.031
procyanidin B-2,3,3'-di-O-gallate
Oryctolagus cuniculus
-
IC50: 0.031 mM
0.024
procyanidin B-5,3,3'-di-O-gallate
Oryctolagus cuniculus
-
IC50: 0.024 mM
0.00127
propan-2-yl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.00047
propan-2-yl 4-(3-chloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.0133
propan-2-yl 4-[3-chloro-4-(2-hydroxyanilino)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.02
propan-2-yl 4-[3-chloro-4-(morpholin-4-yl)-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl]benzoate
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.0003
propyl 4-(3,4-dichloro-2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)benzoate
Homo sapiens
Q7L5N7
pH 7.4, 37°C
0.08
quercetin
Rattus norvegicus
-
IC50: 0.08 mM
0.183
tetradecanoic acid
Rattus norvegicus
-
pH 6.9, 37°C
0.032
theaflavin
Oryctolagus cuniculus
-
IC50: 0.032 mM
0.039
theaflavin-3'-O-gallate
Oryctolagus cuniculus
-
IC50: 0.039 mM
0.028
theaflavin-3,3'-di-O-gallate
Oryctolagus cuniculus
-
IC50: 0.028 mM
0.058
theaflavin-3-O-gallate
Oryctolagus cuniculus
-
IC50: 0.058 mM
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.0000041
-
median activity of lyso-PAF-acetyltransferase in leukocyte homogenates of patients with heart failure
0.000017
brain, Ca2+ independent lyso-PAF AT activity in the presence of EDTA, in the presence of Ca2+ 0.000104
0.000104
spleen, Ca2+ independent lyso-PAF AT activity in the presence of EDTA, in the presence of Ca2+ 0.000470
0.0002
-
kidney cortex; liver
0.00033
lung, Ca2+ independent lyso-PAF AT activity in the presence of EDTA, in the presence of Ca2+ 0.000452
0.0004
-
liver specific activity is reduced in presence of dexamethasone and medroxyprogesterone
0.001
-
spleen specific activity is reduced in presence of dexamethasone
0.002
-
kidney medulla
0.0021
-
A23187 stimulated cell
0.0026
-
bone marrow
0.0039
-
lymph nodes
0.004
-
lung; thymus
0.01
-
spleen microsome
additional information
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7
-
assay at
7.2 - 7.4
-
-
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
23
-
assay at
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
primary cultured cells of
Manually annotated by BRENDA team
-
differentiated
Manually annotated by BRENDA team
-
human mesangial cell line
Manually annotated by BRENDA team
-
activity is enhanced in H2O2-treated cells; H2O2-stimulated
Manually annotated by BRENDA team
-
peritoneal macrophage
Manually annotated by BRENDA team
mRNA and protein expressed in; mRNA transcript and protein are predominatly expressed in experimental allergic encephalomyelitis (EAE) mice
Manually annotated by BRENDA team
-
mastocytoma cell, mucosal-type
Manually annotated by BRENDA team
enzymatic activity and mRNA transcripts are elevated in experimental allergic encephalomyelitis (EAE) mice; experimental allergic encephalomyelitis (EAE) mice, after 12d, 19d, and 34d removed
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
29000
-
x * 29000, SDS-PAGE and affinity labelling experiments
60000
determined by SDS-PAGE and Western Blot analysis
800000
-
MW after gel filtration, aggregate of several proteins or protein aggregates coated with lipids
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
?
-
x * 29000, SDS-PAGE and affinity labelling experiments
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
phosphoprotein
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
37
-
85% loss of activity after 2 h, 35% loss of activity after 2 h in the presence of DTT and 1-alkyl-2-lyso-sn-glycero-3-phosphate, microsomal preparation
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
1-alkyl-sn-glycero-3-phosphocholine at low concentration and lysophosphatidylcholine stabilizes microsomal preparation
-
dithiothreitol, 1 mM stabilizes microsomal preparation
-
stable to lyophilization
-
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
cell extracts are prepared
-
LPCAT1 is partially purified from microsomes from mouse tissue using a DEAE-Sepharose column
partial
-
solubilization in sodium deoxycholate, precipitation by ammonium sulfate, ultragel AcA-22 chromatography, DEAE-sepharose CL-6B chromatography, covalent chromatography with thiopropyl-sepharose 6B
-
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
expression in CHO-S and CHO-S-PAFR cells; gene LPCAT2, recombinant expression of FLAG-tagged human LPCAT2 in CHO cells
for transfection of CHO-K1 cells
gene Lpcat2, quantitative realtime PCR exprssion analysis
gene LPCAT2, recombinant expression of FLAG-tagged mouse LPCAT2 in CHO cells, stable recombinant enzyme expression in RAW264.7 cells
stable recombinant enzyme expression in RAW264.7 cells, recombinant expression in CHO-S-PAFR cells
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
3-hexanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone, 3-decanoyloxy-2-methoxy-5-methyl-1,4-benzoquinone, and 2-methoxy-5-methyl-3-tetradecanoyloxy-1,4-benzoquinone also inhibit the expression of the enzyme mRNA
fatty acid esters of fumigatin reduce lipopolysaccharide-stimulated transcription of lyso-PAF acetyltransferase/LPCAT2 mRNA in bone marrow-derived macrophages
lysoPAF-AT shows a significant activation after 1-h infection with a maximum activity at 2-h infection with Salmonella enteritidis
-
stimulation of enzyme expression by lipopolysaccharides
under inflammatory conditions, LPCAT2, but not LPCAT1, is activated and upregulated to produce the platelet-activating factor
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
F174A
mutation of hydrophobic residue for measuring the remaining activity using acetyl-CoA and palmitoyl-CoA as acyl donors
I160A
mutation of hydrophobic residue for measuring the remaining activity using acetyl-CoA and palmitoyl-CoA as acyl donors
I162A
mutation of hydrophobic residue for measuring the remaining activity using acetyl-CoA and palmitoyl-CoA as acyl donors
I167A
mutation of hydrophobic residue for measuring the remaining activity using acetyl-CoA and palmitoyl-CoA as acyl donors
I170A
mutation of hydrophobic residue for measuring the remaining activity using acetyl-CoA and palmitoyl-CoA as acyl donors
L166A
mutation of hydrophobic residue for measuring the remaining activity using acetyl-CoA and palmitoyl-CoA as acyl donors
V173A
mutation of hydrophobic residue for measuring the remaining activity using acetyl-CoA and palmitoyl-CoA as acyl donors
V175A
mutation of hydrophobic residue for measuring the remaining activity using acetyl-CoA and palmitoyl-CoA as acyl donors
W163A
mutation of hydrophobic residue for measuring the remaining activity using acetyl-CoA and palmitoyl-CoA as acyl donors
Y169A
mutation of hydrophobic residue for measuring the remaining activity using acetyl-CoA and palmitoyl-CoA as acyl donors
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
analysis
drug development
medicine